X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs PIRAMAL ENTERPRISES - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD PIRAMAL ENTERPRISES LUPIN LTD/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 16.6 36.0 46.3% View Chart
P/BV x 3.9 3.6 108.3% View Chart
Dividend Yield % 0.8 0.7 117.0%  

Financials

 LUPIN LTD   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    LUPIN LTD
Mar-16
PIRAMAL ENTERPRISES
Mar-16
LUPIN LTD/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs2,1271,065 199.7%   
Low Rs1,294805 160.8%   
Sales per share (Unadj.) Rs304.1383.0 79.4%  
Earnings per share (Unadj.) Rs50.455.1 91.5%  
Cash flow per share (Unadj.) Rs60.774.1 81.9%  
Dividends per share (Unadj.) Rs7.5017.50 42.9%  
Dividend yield (eoy) %0.41.9 23.4%  
Book value per share (Unadj.) Rs243.8719.9 33.9%  
Shares outstanding (eoy) m450.58172.56 261.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.62.4 230.5%   
Avg P/E ratio x33.917.0 200.0%  
P/CF ratio (eoy) x28.212.6 223.3%  
Price / Book Value ratio x7.01.3 540.2%  
Dividend payout %14.931.8 46.8%   
Avg Mkt Cap Rs m770,740161,344 477.7%   
No. of employees `00016.43.8 432.2%   
Total wages/salary Rs m21,07716,898 124.7%   
Avg. sales/employee Rs Th8,379.617,472.6 48.0%   
Avg. wages/employee Rs Th1,289.04,466.9 28.9%   
Avg. net profit/employee Rs Th1,388.72,512.8 55.3%   
INCOME DATA
Net Sales Rs m137,01666,099 207.3%  
Other income Rs m1,8772,425 77.4%   
Total revenues Rs m138,89368,524 202.7%   
Gross profit Rs m37,53518,723 200.5%  
Depreciation Rs m4,6353,274 141.6%   
Interest Rs m4469,388 4.8%   
Profit before tax Rs m34,3308,485 404.6%   
Minority Interest Rs m-883 -2,654.5%   
Prior Period Items Rs m01,593 0.0%   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m11,5361,032 1,117.9%   
Profit after tax Rs m22,7079,506 238.9%  
Gross profit margin %27.428.3 96.7%  
Effective tax rate %33.612.2 276.3%   
Net profit margin %16.614.4 115.2%  
BALANCE SHEET DATA
Current assets Rs m97,79047,488 205.9%   
Current liabilities Rs m53,872104,362 51.6%   
Net working cap to sales %32.1-86.0 -37.3%  
Current ratio x1.80.5 398.9%  
Inventory Days Days8541 208.5%  
Debtors Days Days12151 237.0%  
Net fixed assets Rs m86,37926,532 325.6%   
Share capital Rs m901345 261.1%   
"Free" reserves Rs m105,735114,024 92.7%   
Net worth Rs m109,844124,221 88.4%   
Long term debt Rs m53,73975,812 70.9%   
Total assets Rs m224,378308,356 72.8%  
Interest coverage x77.91.9 4,093.8%   
Debt to equity ratio x0.50.6 80.2%  
Sales to assets ratio x0.60.2 284.9%   
Return on assets %10.36.1 168.4%  
Return on equity %20.77.7 270.1%  
Return on capital %21.210.0 212.9%  
Exports to sales %49.117.2 285.5%   
Imports to sales %7.46.6 112.7%   
Exports (fob) Rs m67,24411,362 591.9%   
Imports (cif) Rs m10,1994,364 233.7%   
Fx inflow Rs m71,40514,435 494.7%   
Fx outflow Rs m17,8075,183 343.6%   
Net fx Rs m53,5989,253 579.3%   
CASH FLOW
From Operations Rs m-3,690-67,773 5.4%  
From Investments Rs m-69,434-8,768 791.9%  
From Financial Activity Rs m58,12676,199 76.3%  
Net Cashflow Rs m-14,998-342 4,380.3%  

Share Holding

Indian Promoters % 46.6 52.9 88.1%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 4.0 282.5%  
FIIs % 31.9 26.6 119.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 16.5 61.2%  
Shareholders   98,259 93,274 105.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PLETHICO PHARMA  WOCKHARDT LTD.  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Aug 22, 2017 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS